PREPARATION AND EVALUATION OF IGURATIMOD ORAL FORMULATION USING CYCLODEXTRIN NANOSPONGES

Authors

  • MADHAVI M. GITAM School of Pharmacy, GITAM Deemed to be University, Hyderabad 502329, Telangana, India
  • SHIVA KUMAR G. GITAM School of Pharmacy, GITAM Deemed to be University, Hyderabad 502329, Telangana, India https://orcid.org/0000-0002-3334-1333

DOI:

https://doi.org/10.22159/ijap.2022v14i5.45044

Keywords:

Iguratimod, rheumatoid arthritis, Cyclodextrin-based nanosponges, Box-Behnken design

Abstract

Objective: Cyclodextrin nanosponges have unfolded themselves as budding delivery aids for intractable molecules that face difficulty in formulation.

Methods: The present research aimed at preparation of cyclodextrin based nanosponges employing diphenylcarbonate crosslinker as reported elsewhere. Box-Behnken design was adopted to evaluate the effects of factors (reaction temperature, reaction time and stirring speed) on practical yield and particle size. Based on a numerical optimization technique five batches of nanosponge formulations with varying molar ratios (1:2, 1:4, 1:6, 1:8 and 1:10) were formulated and evaluated.

Results: The drug loading into optimized β–CD (NS14, NS16) was carried out by by freeze drying method with maximum drug loading of 32% displayed by IGNS14. The particle sizes of Iguratimod-loaded nanosponges range between 178 to 181 nm with lower polydispersity indices. The formulation IGNS14 and IGNS16 displayed optimal zetapotential of -27 and -26 mV which is sufficient to stabilize the colloidal nanosuspension. The dissolution of both nanosponges was significantly higher (>98%) and controlled when compared to pure drug (34%). Retention of drug in the optimized nanosponges was observed which was released slowly over time. The PXRD confirm the formation of paracrystalline nanosponges that are spherical in shape with no interaction amongst the drug and excipients.

Conclusion: The cyclodextrin-based NS of Iguratimod were a probable alternative for drug delivery with improved physicochemical properties and therapeutic efficacy.

Downloads

Download data is not yet available.

References

Trotta F, Zanetti M, Cavalli R. Cyclodextrin-based nanosponges as drug carriers. Beilstein J Org Chem 2012; 8:2091-2099.

Bhowmik, Himangshu & Venkatesh, D. & Kuila, Anuttam & Kumar, Kammari. Nanosponges: A review. International Journal of Applied Pharmaceutics, 2018 10. 1. 10.

Venuti V, Rossi B, Mele A, Melone L, Punta C, Majolino D, Masciovecchio C, Caldera F, Trotta F. Tuning structural parameters for the optimization of drug delivery performance of cyclodextrin-based nanosponges. Expert Opi

n Drug Deliv 2017; 14(3):331-340.

Kaur, Simranjot & Kumar, Sandeep. The Nanosponges: An Innovative Drug Delivery System. Asian Journal of Pharmaceutical and Clinical Research. 2019, 60-67.

Trotta F, Cavalli R. Characterization and Applications of New Hyper-Cross-Linked Cyclodextrins. Compos Interfaces 2009; 16(1):39-48

Swaminathan, S., Vavia, P.R., Trotta, F., Cavalli, R., Tumbiolo, S., Bertinetti, L. and Coluccia, S. Structural evidence of differential forms of nanosponges of beta-cyclodextrin and its effect on solubilization of a model drug. Journal of inclusion phenomena and macrocyclic chemistry, 2013, 76(1-2), pp.201-211.

Chilajwar SV, Pednekar PP, Jadhav KR, Gupta GJC, Kadam VJ. Cyclodextrin-based nanosponges: a propitious platform for enhancing drug delivery. Expert Opin Drug Deliv 2013; 11:111–120.

Chando Anita, Momin Munira, Quadros Mural, Lalka Shaily, Topical nanocarriers for management of Rheumatoid Arthritis: A review, Biomedicine & Pharmacotherapy, 2021, Volume 141, 111880.

Takeba Y, Suzuki N, Wakisaka S, Nagafuchi H, Mihara S, Kaneko A, Asai T, Sakane T. Effects of Actarit on synovial cell functions in patients with rheumatoid arthritis. J Rheumatol 1999; 26:25–33.

Janakiraman K, Krishnaswami V, Rajendran V, Natesan S, Kandasamy R. Novel nano therapeutic materials for the effective treatment of rheumatoid arthritis-recent insights. Mater Today Commun. 2018 Dec; 17:200-213.

Nagarjun Rangaraj, Sravanthi Reddy Pailla, Paramesh Chowta, and SunithaSampathi: Fabrication of Ibrutinib Nanosuspension by Quality by Design Approach: Intended for Enhanced Oral Bioavailability and Diminished Fast Fed Variability. AAPS PharmSciTech 2019; 20:326.

Bowden GD, Pichler BJ, Maurer A. A Design of Experiments (DoE) Approach Accelerates the Optimization of Copper-Mediated 18F-Fluorination Reactions of Arylstannanes. Sci 2019; Rep 9: 11370.

Anandam S, Selvamuthukumar S. Fabrication of cyclodextrin nanosponges for quercetin delivery: Physicochemical characterization, photostability, and antioxidant effects. Journal of Materials Science. 2014;49(23):8140-8153.

Anandam Singireddy, Selvamuthu kumar Subramanian. Cyclodextrin nanosponges to enhance the dissolution profile of quercetin by inclusion complex formation. Particulate Science and Technology 2016; 34(3):341-346.

Darandale SS, Vavia PR. Cyclodextrin-based nanosponges of curcumin: formulation and physicochemical characterization. J InclPhenomMacrocyclChem 2013; 75: 315–322.

Zoppi A, Quevedo MA, Longhi MR. Specific binding capacity of beta-cyclodextrin with cis and trans enalapril: physicochemical characterization and structural studies by molecular modeling. Bioorg Med Chem. 2008; 16(18):8403– 8412.

Solunke, Rahul & Borge, Uday & Murthy, Krishna & Deshmukh, Madhuri & Shete, Rajkumar. Formulation and evaluation of gliclazide nanosponges. International Journal of Applied Pharmaceutics. 2019, 11. 181-189.

El-Assal, Mona. Nano-Sponge Novel Drug Delivery System as Carrier of Anti-Hypertensive Drug. International Journal of Pharmacy and Pharmaceutical Sciences. 2019, 47-63.

Published

04-07-2022

How to Cite

M., M., & G., S. K. (2022). PREPARATION AND EVALUATION OF IGURATIMOD ORAL FORMULATION USING CYCLODEXTRIN NANOSPONGES. International Journal of Applied Pharmaceutics, 14(5). https://doi.org/10.22159/ijap.2022v14i5.45044

Issue

Section

Original Article(s)